Hsbc Holdings PLC Nurix Therapeutics, Inc. Transaction History

Hsbc Holdings PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$12.02 - $21.3 $200,012 - $354,432	-16,640 Reduced 49.41%	17,038 $355,000
Q1 2024 May 15, 2024	SELL	$7.77 - $15.66 $261,421 - $526,880	-33,645 Reduced 49.98%	33,678 $495,000
Q4 2023 Feb 12, 2024	BUY	$4.25 - $10.71 $81,846 - $206,253	19,258 Added 40.07%	67,323 $694,000
Q3 2023 Nov 13, 2023	BUY	$7.86 - $10.08 $107,964 - $138,458	13,736 Added 40.01%	48,065 $377,000
Q2 2023 Aug 11, 2023	BUY	$8.7 - $13.28 $77,229 - $117,886	8,877 Added 34.88%	34,329 $342,000
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $14,611 - $22,634	1,707 Added 7.19%	25,452 $226,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $114,090 - $168,820	11,571 Added 95.05%	23,745 $260,000
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $150,105 - $241,166	12,174 New	12,174 $162,000
Q2 2022 Aug 11, 2022	SELL	$7.88 - $14.82 $91,526 - $172,134	-11,615 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $150,298 - $344,384	11,615 New	11,615 $165,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.